Announcements Trials
Browse Landscape

Status

Unknown 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 4

Study Type

Interventional 11Observational 4

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 6HER2-positive Breast Cancer 4Salivary Gland Neoplasms 1HER2-positive Advanced Breast Cancer 1

Interventions

pyrotinib 4neratinib 2tucatinib 1trastuzumab deruxtecan 1pertuzumab 1Trastuzumab 1Hospital Information Systems 1Genetic Testing 1Electronic Health Records 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Observational × HER2-positive Breast Cancer × pyrotinib × Clear all
NCT07470203 2026-03-13

Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer

Peking University Cancer Hospital & Institute

Not yet recruiting
42 enrolled
Breast

HER2-positive Breast Cancer

NCT06754059 2025-01-01

Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC

Fujian Medical University Union Hospital

Recruiting
60 enrolled
Breast

HER2-positive Breast Cancer

NCT05561686 2022-09-30

Real-world Study of Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

Hunan Cancer Hospital

Unknown
100 enrolled
Breast

HER2-positive Breast Cancer

NCT04756921 2021-02-16

18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response

Fudan University

Completed
30 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡